clinical trial · NCT06708260
A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME
Diabetic Macular Edema (DME)ENN0403, low doseENN0403, high dose
brief summary
This is a multicenter, randomized, parallel study to evaluate the efficacy and safety of two doses of ENN0403 in subjects with diabetic macular edema (DME). Approximately 60 subjects will be randomized to receive ENN0403 capsule orally once a day at the low dose or high dose with a 1:1 ratio. The study period consisted of up to 2 weeks of screening, 12 weeks of treatment and 2 weeks of follow-up, and the entire trial period was up to 16 weeks.
started
Dec 12, 2024
primary completion
Dec 1, 2025
completion
Feb 1, 2026
last updated
Feb 21, 2025
official title
A Phase 2, Multicenter, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Two Doses of ENN0403 in Subjects with Diabetic Macular Edema (DME)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol